findmyKOL

Mary Rinella, MD

Enriched profile

Professor of Medicine, Gastroenterology, Hepatology and Nutrition · University of Chicago

ORCIDNPI
Region🇺🇸 Chicago, IL · Midwest · United StatesSpecialtyGastroenterologyFocusLiver Disease Diagnosis and Treatment+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2023–2025NIH funding2006–2011

Mary Rinella is Professor of Medicine, Gastroenterology, Hepatology and Nutrition at University of Chicago. OpenAlex indexes 279 publications with 48,331 citations (h-index 71); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Gastroenterology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Mary E. Rinella, MD, is Professor of Medicine, Gastroenterology, Hepatology and Nutrition at University of Chicago (Pritzker School of Medicine / UChicago Medicine). The public record shows 279 publications with 48,331 citations (h-index 71), centered on Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Diet, Metabolism, and Disease. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 10 companies, 2 NIH-funded awards (2006–2011).

  • Most recent indexed publication: 2026 · Hepatology communications
  • Top research focus: Liver Disease Diagnosis and Treatment
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Obesity2 trialsNASH / NAFLD / MASH1 trialNon-alcoholic Fatty Liver Disease1 trialLiver Diseases1 trialFatty Liver1 trialFatty Liver, Alcoholic1 trialType 2 Diabetes1 trialHypertension1 trial

Research focus

OpenAlex concept fingerprint
Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationDiet, Metabolism, and DiseaseLiver Diseases and ImmunityAlcohol Consumption and Health Effects

Drugs & molecules

across trials, industry payments and publications
Rezdiffrageneric · ResmetiromClinical trialsIndustry payments18PublicationsGattexgeneric · TeduglutideClinical trialsIndustry payments1PublicationsTerlivazgeneric · TerlipressinClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Eli Lilly and CompanyClinical trials1Industry payments3GlaxoSmithKline, LLC.Clinical trialsIndustry payments24Novo Nordisk IncClinical trialsIndustry payments23

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
279publications

Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.

48,331citations

Total citations across indexed works.

71h-index

Hirsch index (OpenAlex). i10-index 137.

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials
10companies · 2023–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2006–2011

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    66.7%
    Bile Acid32.6%
    Ursodiol100%
    Part D14 patients
    Rifamycin Antibacterial15.6%
    Xifaxan100%
    Part D<11 patients
  • Cardiovascular

    19.9%
    Aldosterone antagonist (MRA)11.3%
    Spironolactone100%
    Part D<11 patients
    Beta blocker8.5%
    Carvedilol100%
    Part D<11 patients
  • Cancer & immunology

    13.5%
    Purine Antimetabolite13.5%
    Azathioprine100%
    Part D<11 patients
Where care is delivered (Part B)57.2% facility · 42.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20062011 per NIH RePORTER. The latest:

8 more award records behind the reveal.Reveal →

Congress activity

Updated 27 Aug 2026

1 congress contribution (2025) across ADA per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • X / Twitter

    x.com/marurinella

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    aasld.org/governing-board/mary-e-mccarthy-rinella-md-faasld

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aasld.org
  • Other

    aasld.org/liver-fellow-network/core-series/podcast/whats-new-nash-mary-rinella

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aasld.org

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Lead author/Chair

    2023 AASLD Clinical Practice Guidance on diagnosis and management of NAFLD/MASLD

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu
  • Director

    Metabolic and Fatty Liver Program, University of Chicago

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu
  • Director of Clinical Trials

    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.